Nevertheless, we deeply believe that the analyses performed may aid in presenting a brief assessment of the role of single-agent PARPi for managing patients with BRCA-mutated HER2-negative advanced breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.